Titre : Psychothérapie de groupe

Psychothérapie de groupe : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Psychothérapie de groupe : Questions médicales les plus fréquentes", "headline": "Psychothérapie de groupe : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Psychothérapie de groupe : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-04", "dateModified": "2025-04-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Psychothérapie de groupe" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Thérapie socio-environnementale", "url": "https://questionsmedicales.fr/mesh/D012960", "about": { "@type": "MedicalCondition", "name": "Thérapie socio-environnementale", "code": { "@type": "MedicalCode", "code": "D012960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Thérapie de couple", "alternateName": "Couples Therapy", "url": "https://questionsmedicales.fr/mesh/D019546", "about": { "@type": "MedicalCondition", "name": "Thérapie de couple", "code": { "@type": "MedicalCode", "code": "D019546", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864.581.136" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Thérapie conjugale", "alternateName": "Marital Therapy", "url": "https://questionsmedicales.fr/mesh/D008388", "about": { "@type": "MedicalCondition", "name": "Thérapie conjugale", "code": { "@type": "MedicalCode", "code": "D008388", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864.581.136.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Thérapie familiale", "alternateName": "Family Therapy", "url": "https://questionsmedicales.fr/mesh/D005196", "about": { "@type": "MedicalCondition", "name": "Thérapie familiale", "code": { "@type": "MedicalCode", "code": "D005196", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864.581.273" } } }, { "@type": "MedicalWebPage", "name": "Psychodrame", "alternateName": "Psychodrama", "url": "https://questionsmedicales.fr/mesh/D011577", "about": { "@type": "MedicalCondition", "name": "Psychodrame", "code": { "@type": "MedicalCode", "code": "D011577", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864.581.679" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Jeu de rôle", "alternateName": "Role Playing", "url": "https://questionsmedicales.fr/mesh/D012381", "about": { "@type": "MedicalCondition", "name": "Jeu de rôle", "code": { "@type": "MedicalCode", "code": "D012381", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864.581.679.653" } } } ] }, { "@type": "MedicalWebPage", "name": "Groupes d'apprentissage en commun", "alternateName": "Sensitivity Training Groups", "url": "https://questionsmedicales.fr/mesh/D012681", "about": { "@type": "MedicalCondition", "name": "Groupes d'apprentissage en commun", "code": { "@type": "MedicalCode", "code": "D012681", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F04.754.864.581.813" } } } ], "about": { "@type": "MedicalCondition", "name": "Psychothérapie de groupe", "alternateName": "Psychotherapy, Group", "code": { "@type": "MedicalCode", "code": "D011615", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "David Kealy", "url": "https://questionsmedicales.fr/author/David%20Kealy", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, University of British Columbia, Vancouver, Canada." } }, { "@type": "Person", "name": "Jenny Rosendahl", "url": "https://questionsmedicales.fr/author/Jenny%20Rosendahl", "affiliation": { "@type": "Organization", "name": "Institute of Psychosocial Medicine, Psychotherapy and Psychooncology, Friedrich Schiller University Jena, Jena University Hospital, Jena, Germany (Rosendahl, Strauss); Department of Psychology, Brigham Young University, Provo, Utah (Alldredge, Burlingame)." } }, { "@type": "Person", "name": "Giorgio A Tasca", "url": "https://questionsmedicales.fr/author/Giorgio%20A%20Tasca", "affiliation": { "@type": "Organization", "name": "Clinical Epidemiology Program." } }, { "@type": "Person", "name": "Anthony S Joyce", "url": "https://questionsmedicales.fr/author/Anthony%20S%20Joyce", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, University of Alberta." } }, { "@type": "Person", "name": "John S Ogrodniczuk", "url": "https://questionsmedicales.fr/author/John%20S%20Ogrodniczuk", "affiliation": { "@type": "Organization", "name": "Psychotherapy Program, Department of Psychiatry, University of British Columbia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36253300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clgc.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.", "datePublished": "2024-10-20", "url": "https://questionsmedicales.fr/article/39428439", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-76355-4" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Disciplines et activités comportementales", "item": "https://questionsmedicales.fr/mesh/D004191" }, { "@type": "ListItem", "position": 3, "name": "Psychothérapie", "item": "https://questionsmedicales.fr/mesh/D011613" }, { "@type": "ListItem", "position": 4, "name": "Thérapie socio-environnementale", "item": "https://questionsmedicales.fr/mesh/D012960" }, { "@type": "ListItem", "position": 5, "name": "Psychothérapie de groupe", "item": "https://questionsmedicales.fr/mesh/D011615" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Psychothérapie de groupe - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Psychothérapie de groupe", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Psychothérapie de groupe", "description": "Comment diagnostiquer un besoin de psychothérapie de groupe ?\nQuels troubles bénéficient de la psychothérapie de groupe ?\nQui peut bénéficier d'une psychothérapie de groupe ?\nComment évaluer l'efficacité d'une psychothérapie de groupe ?\nQuels outils sont utilisés pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D011615?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Psychothérapie de groupe", "description": "Quels symptômes indiquent un besoin de psychothérapie de groupe ?\nComment les symptômes évoluent-ils en groupe ?\nLes symptômes physiques peuvent-ils être liés à des troubles psychologiques ?\nComment identifier les symptômes d'un participant en groupe ?\nLes symptômes peuvent-ils s'aggraver en groupe ?", "url": "https://questionsmedicales.fr/mesh/D011615?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Psychothérapie de groupe", "description": "Comment la psychothérapie de groupe aide-t-elle à la prévention ?\nQuels sont les signes préventifs d'un besoin de groupe ?\nLa prévention est-elle efficace en groupe ?\nComment intégrer la prévention dans les séances ?\nLes groupes de soutien sont-ils une forme de prévention ?", "url": "https://questionsmedicales.fr/mesh/D011615?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Psychothérapie de groupe", "description": "Quels types de thérapies sont utilisés en groupe ?\nQuelle est la durée typique d'une psychothérapie de groupe ?\nComment se déroule une séance de psychothérapie de groupe ?\nLes médicaments sont-ils utilisés en complément ?\nComment choisir un groupe de psychothérapie ?", "url": "https://questionsmedicales.fr/mesh/D011615?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Psychothérapie de groupe", "description": "Quelles complications peuvent survenir en psychothérapie de groupe ?\nComment gérer les complications en groupe ?\nLes participants peuvent-ils se sentir mal à l'aise ?\nComment prévenir les complications en groupe ?\nLes complications peuvent-elles affecter l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D011615?mesh_terms=Prostatic+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Psychothérapie de groupe", "description": "Quels facteurs de risque influencent la psychothérapie de groupe ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe stress est-il un facteur de risque ?\nComment le contexte socio-économique affecte-t-il la psychothérapie de groupe ?\nLes événements traumatiques augmentent-ils les risques ?", "url": "https://questionsmedicales.fr/mesh/D011615?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un besoin de psychothérapie de groupe ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel évalue les symptômes et l'impact sur la vie quotidienne." } }, { "@type": "Question", "name": "Quels troubles bénéficient de la psychothérapie de groupe ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les troubles anxieux, dépressifs et les addictions sont souvent traités en groupe." } }, { "@type": "Question", "name": "Qui peut bénéficier d'une psychothérapie de groupe ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes cherchant du soutien social et des stratégies de coping peuvent en bénéficier." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité d'une psychothérapie de groupe ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité se mesure par l'amélioration des symptômes et la satisfaction des participants." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des questionnaires et des entretiens cliniques sont souvent utilisés pour le diagnostic." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin de psychothérapie de groupe ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Isolement social, anxiété, dépression et difficultés relationnelles sont des indicateurs." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils en groupe ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les participants peuvent partager leurs expériences, ce qui peut réduire l'anxiété et la dépression." } }, { "@type": "Question", "name": "Les symptômes physiques peuvent-ils être liés à des troubles psychologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes physiques comme des douleurs peuvent être liés à des troubles psychologiques." } }, { "@type": "Question", "name": "Comment identifier les symptômes d'un participant en groupe ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Le thérapeute observe les interactions et les réactions des participants pendant les sessions." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver en groupe ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Dans certains cas, des conflits peuvent survenir, aggravant les symptômes de certains participants." } }, { "@type": "Question", "name": "Comment la psychothérapie de groupe aide-t-elle à la prévention ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Elle favorise le soutien social et l'apprentissage de stratégies de coping pour prévenir les rechutes." } }, { "@type": "Question", "name": "Quels sont les signes préventifs d'un besoin de groupe ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un sentiment d'isolement, des changements d'humeur ou des difficultés relationnelles peuvent être des signes." } }, { "@type": "Question", "name": "La prévention est-elle efficace en groupe ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les groupes offrent un environnement de soutien qui peut réduire le risque de troubles mentaux." } }, { "@type": "Question", "name": "Comment intégrer la prévention dans les séances ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapeutes peuvent inclure des discussions sur la gestion du stress et des techniques de relaxation." } }, { "@type": "Question", "name": "Les groupes de soutien sont-ils une forme de prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les groupes de soutien peuvent aider à prévenir l'aggravation des troubles psychologiques." } }, { "@type": "Question", "name": "Quels types de thérapies sont utilisés en groupe ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies cognitivo-comportementales et humanistes sont couramment utilisées." } }, { "@type": "Question", "name": "Quelle est la durée typique d'une psychothérapie de groupe ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les sessions durent généralement entre 1 et 2 heures, une fois par semaine." } }, { "@type": "Question", "name": "Comment se déroule une séance de psychothérapie de groupe ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Une séance commence par des échanges, suivis d'activités thérapeutiques et de discussions." } }, { "@type": "Question", "name": "Les médicaments sont-ils utilisés en complément ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments peuvent être prescrits en complément de la psychothérapie de groupe." } }, { "@type": "Question", "name": "Comment choisir un groupe de psychothérapie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il est important de considérer les objectifs, le type de thérapie et la dynamique de groupe." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir en psychothérapie de groupe ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des conflits interpersonnels ou des réactions émotionnelles intenses peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les complications en groupe ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Le thérapeute doit intervenir pour faciliter la communication et résoudre les conflits." } }, { "@type": "Question", "name": "Les participants peuvent-ils se sentir mal à l'aise ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains participants peuvent se sentir vulnérables ou mal à l'aise lors des partages." } }, { "@type": "Question", "name": "Comment prévenir les complications en groupe ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Établir des règles claires et créer un environnement de confiance peut aider à prévenir les complications." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter l'efficacité du traitement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications non gérées peuvent réduire l'efficacité de la psychothérapie de groupe." } }, { "@type": "Question", "name": "Quels facteurs de risque influencent la psychothérapie de groupe ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement social, les antécédents de troubles mentaux et le manque de soutien familial sont des facteurs de risque." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles mentaux peuvent augmenter le risque de problèmes psychologiques." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un stress chronique peut exacerber les problèmes psychologiques et influencer la participation au groupe." } }, { "@type": "Question", "name": "Comment le contexte socio-économique affecte-t-il la psychothérapie de groupe ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Un contexte socio-économique défavorable peut limiter l'accès aux soins et augmenter le stress." } }, { "@type": "Question", "name": "Les événements traumatiques augmentent-ils les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des événements traumatiques peuvent augmenter le risque de troubles mentaux nécessitant une psychothérapie de groupe." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o... PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u... More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ... Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...